NEW BRUNSWICK, N.J.,
July 17, 2018 /PRNewswire/ -- Johnson
& Johnson (NYSE: JNJ) today announced sales of $20.8 billion for the second quarter of 2018, an
increase of 10.6% as compared to the second quarter of 2017.
Operational sales results increased 8.7% and the positive impact of
currency was 1.9%. Domestic sales increased 9.4%. International
sales increased 11.8%, reflecting operational growth of 7.9% and a
positive currency impact of 3.9%. Excluding the net impact of
acquisitions and divestitures, on an operational basis, worldwide
sales increased 6.3%, domestic sales increased 5.7% and
international sales increased 6.8%.*
Net earnings and diluted earnings per share for the second
quarter of 2018 were $4.0 billion and
$1.45, respectively. Second-quarter
2018 net earnings included after-tax intangible amortization
expense of approximately $1.0 billion
and a charge for after-tax special items of approximately
$0.8 billion. Second-quarter 2017 net
earnings included after-tax intangible amortization expense of
approximately $0.4 billion and a
charge for after-tax special items of approximately $0.8 billion. Excluding after-tax intangible
amortization expense and special items, adjusted net earnings for
the current quarter were $5.7 billion
and adjusted diluted earnings per share were $2.10, representing increases of 14.0% and 14.8%,
respectively, as compared to the same period in 2017.* On an
operational basis, adjusted diluted earnings per share also
increased 11.5%.* A reconciliation of non-GAAP financial
measures is included as an accompanying schedule.
"Our strong second-quarter results reflect double-digit growth
in our Pharmaceutical business and the accelerating sales momentum
in our Medical Devices business, driven by the continued growth of
our market leading products and strategic new launches. We remain
focused on investing in innovation and meeting the needs of our
customers by delivering innovative products and solutions that
position the company to deliver long-term, sustainable growth,"
said Alex Gorsky, Chairman and Chief
Executive Officer. "Our talented J&J colleagues are united in
our efforts to address some of the most critical health and
consumer needs of people around the world."
The Company updated its sales guidance for the full-year 2018 to
a range of $80.5 to $81.3 billion. This reflects an increase in
expected operational growth to a range of 4.5% to 5.5%, partially
offset by the estimated lower favorable impact of currency.
Additionally, the Company updated its adjusted earnings guidance
for full-year 2018 to a range of $8.07 to $8.17 per
share. This reflects an increase in expected operational growth to
a range of 8.5% to 9.9%, partially offset by the estimated lower
favorable impact of currency.
Segment Sales Performance
Worldwide Consumer sales of $3.5
billion for the second quarter 2018 represented an increase
of 0.7% versus the prior year, consisting of an operational
decrease of 0.4% and a positive impact from currency of 1.1%.
Domestic sales decreased 0.7%, international sales increased 1.9%,
which reflected no change in operational sales and a positive
currency impact of 1.9%. Excluding the net impact of acquisitions
and divestitures, on an operational basis, worldwide sales
increased 0.9%, domestic sales decreased 0.7% and international
sales increased 2.1%*.
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were driven by over-the-counter
products including TYLENOL analgesics and digestive health
products, international beauty products primarily NEUTROGENA, OGX
and Dr. Ci Labo, partially offset by lower sales of baby care
products. During the quarter, the divestiture of the anti‐dandruff
shampoo brand NIZORAL and certain other ketoconazole‐based shampoo
brands was completed.
Worldwide Pharmaceutical sales of $10.4
billion for the second quarter 2018 represented an increase
of 19.9% versus the prior year with an operational increase of
17.6% and a positive impact from currency of 2.3%. Domestic sales
increased 17.7%; international sales increased 22.9%, which
reflected an operational increase of 17.5% and a positive currency
impact of 5.4%. Sales included the impact of Actelion Ltd which
contributed 6.6%, to worldwide operational sales growth. Excluding
the net impact of acquisitions and divestitures, on an operational
basis, worldwide sales increased 11.0%, domestic sales increased
10.2% and international sales increased 11.9%.*
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were driven by STELARA
(ustekinumab), a biologic for the treatment of a number of
immune-mediated inflammatory diseases, ZYTIGA (abiraterone
acetate), an oral, once-daily medication for use in combination
with prednisone for the treatment of metastatic,
castration-resistant prostate cancer, DARZALEX (daratumumab), for
the treatment of patients with multiple myeloma, IMBRUVICA
(ibrutinib), an oral, once-daily therapy approved for use in
treating certain B-cell malignancies, a type of blood or lymph node
cancer, TREMFYA (guselkumab), for the treatment of adults living
with moderate to severe plaque psoriasis. SIMPONI/SIMPONI ARIA
(golimumab), a biologic for the treatment of a number of immune-
mediated inflammatory diseases, INVEGA
SUSTENNA/XEPLION/TRINZA/TREVICTA (paliperidone palmitate),
long-acting, injectable atypical antipsychotics for the treatment
of schizophrenia in adults, and XARELTO (rivaroxaban), an oral
anticoagulant.
During the quarter, the U.S. Food and Drug Administration (FDA)
approved an additional indication for DARZALEX (daratumumab) in
combination with VELCADE (bortezomib), a proteasome inhibitor;
melphalan, an alkylating agent; and prednisone for the treatment of
patients with newly diagnosed multiple myeloma who are ineligible
for autologous stem cell transplant. The European Commission
granted marketing authorization for JULUCA
(dolutegravir/rilpivirine), a two-drug regimen, once-daily,
single-pill for the treatment of HIV-1. A supplemental New Drug
Application was submitted to the FDA seeking to expand the
indication of OPSUMIT (macitentan) to include the treatment of
adults with inoperable chronic thromboembolic pulmonary
hypertension (CTEPH, WHO Group 4) to improve exercise capacity and
pulmonary vascular resistance.
Also in the quarter, the acquisition of BeneVir Biopharm, Inc.,
a privately-held, biopharmaceutical company specializing in the
development of oncolytic immunotherapies, was completed. In
addition, a worldwide collaboration was entered into with
Bristol-Myers Squibb Company to develop and commercialize Factor
XIa inhibitors, including BMS-986177, for the prevention and
treatment of major thrombotic conditions.
Worldwide Medical Devices sales of $7.0
billion for the second quarter 2018 represented an increase
of 3.7% versus the prior year consisting of an operational increase
of 1.9% and a positive currency impact of 1.8%. Domestic sales
increased 1.1%; international sales increased 6.0%, which reflected
an operational increase of 2.5% and a positive currency impact of
3.5%. Excluding the net impact of acquisitions and divestitures, on
an operational basis, worldwide sales increased 2.9%, domestic
sales increased 1.7% and international sales increased 4.1%.*
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were driven by ACUVUE contact lenses
and surgical products in the Vision business; electrophysiology
products in the Interventional Solutions business; biosurgicals and
international endocutters in the Advanced Surgery business; wound
closure products in the General Surgery business and trauma
products in the Orthopaedics business, partially offset by declines
in the Diabetes Care business and spine products in the
Orthopaedics business.
During the quarter, the Company announced acceptance of the
binding offer from Platinum Equity to acquire its LifeScan business
for approximately $2.1 billion,
subject to customary adjustments. The Company also announced
receipt of a binding offer from Fortive Corporation to acquire its
Advanced Sterilization Products business for an aggregate value of
approximately $2.8 billion, subject
to customary adjustments. In addition, the FDA approved iDESIGN
Refractive Studio, part of a next generation LASIK platform that
measures the eye inside and out to enable highly precise
personalized vision correction.
In July, the acquisition of assets from Medical Enterprises
Distribution, LLC, a privately held developer of surgical impactor
technology, including the automated ME1000 Surgical Impactor for
use in hip replacement, was completed.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation
of vibrant lives, thriving communities and forward progress. That's
why for more than 130 years, we have aimed to keep people well at
every age and every stage of life. Today, as the world's largest
and most broadly-based health care company, we are committed to
using our reach and size for good. We strive to improve access and
affordability, create healthier communities, and put a healthy
mind, body and environment within reach of everyone, everywhere. We
are blending our heart, science and ingenuity to profoundly change
the trajectory of health for humanity.
* Operational sales growth excluding the net impact of
acquisitions and divestitures, as well as adjusted net earnings,
adjusted diluted earnings per share and operational adjusted
diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial
measures and should not be considered replacements for, and should
be read together with, the most comparable GAAP financial measures.
Except for guidance measures, reconciliations of these non-GAAP
financial measures to the most directly comparable GAAP financial
measures can be found in the accompanying financial schedules of
the earnings release and the Investor Relations section of the
company's website at www.investor.jnj.com. Johnson &
Johnson does not provide GAAP financial measures on a
forward-looking basis because the company is unable to predict with
reasonable certainty the ultimate outcome of legal proceedings,
unusual gains and losses, acquisition-related expenses and purchase
accounting fair value adjustments without unreasonable effort.
These items are uncertain, depend on various factors, and could be
material to Johnson & Johnson's results computed in accordance
with GAAP.
Johnson & Johnson will conduct a conference call with
investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast
of the call for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website at
www.investor.jnj.com. A replay and podcast will be available
approximately two hours after the live webcast by visiting
www.investor.jnj.com.
Copies of the financial schedules accompanying this press
release are available at www.investor.jnj.com/historical-sales.cfm.
These schedules include supplementary sales data, a condensed
consolidated statement of earnings, reconciliations of non-GAAP
financial measures, and sales of key products/franchises.
Additional information on Johnson & Johnson, including adjusted
income before tax by segment, a pharmaceutical pipeline of selected
compounds in late stage development and a copy of today's earnings
call presentation can be found on the company's website at
www.investor.jnj.com.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial
performance, product development, market position and business
strategy. The reader is cautioned not to rely on these forward-
looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the company to successfully
execute strategic plans, including restructuring plans; the impact
of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or
regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to
applicable laws and regulations, including tax laws, global health
care reforms and import/export and trade laws; trends toward health
care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial
instability of international economies and legal systems and
sovereign risk; increased scrutiny of the health care industry by
government agencies. A further list and descriptions of these
risks, uncertainties and other factors can be found in Johnson
& Johnson's Annual Report on Form 10-K for the fiscal year
ended December 31, 2017, including in
the sections captioned "Cautionary Note Regarding Forward-Looking
Statements" and "Item 1A. Risk Factors," and in the company's
subsequent Quarterly Reports on Form 10-Q and other filings with
the Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov, www.jnj.com or on request from
Johnson & Johnson. Any forward-looking statement made in this
release speaks only as of the date of this release. Johnson &
Johnson does not undertake to update any forward-looking statement
as a result of new information or future events or
developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2018
|
|
2017
|
|
Total
|
|
Operations
|
|
Currency
|
|
2018
|
|
2017
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,476
|
|
1,487
|
|
(0.7)
|
%
|
(0.7)
|
|
-
|
|
$
2,912
|
|
2,901
|
|
0.4
|
%
|
0.4
|
|
-
|
International
|
2,028
|
|
1,991
|
|
1.9
|
|
0.0
|
|
1.9
|
|
3,990
|
|
3,805
|
|
4.9
|
|
0.5
|
|
4.4
|
|
3,504
|
|
3,478
|
|
0.7
|
|
(0.4)
|
|
1.1
|
|
6,902
|
|
6,706
|
|
2.9
|
|
0.4
|
|
2.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
5,899
|
|
5,010
|
|
17.7
|
|
17.7
|
|
-
|
|
11,253
|
|
9,882
|
|
13.9
|
|
13.9
|
|
-
|
International
|
4,455
|
|
3,625
|
|
22.9
|
|
17.5
|
|
5.4
|
|
8,945
|
|
6,998
|
|
27.8
|
|
19.9
|
|
7.9
|
|
10,354
|
|
8,635
|
|
19.9
|
|
17.6
|
|
2.3
|
|
20,198
|
|
16,880
|
|
19.7
|
|
16.4
|
|
3.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,265
|
|
3,229
|
|
1.1
|
|
1.1
|
|
-
|
|
6,426
|
|
6,321
|
|
1.7
|
|
1.7
|
|
-
|
International
|
3,707
|
|
3,497
|
|
6.0
|
|
2.5
|
|
3.5
|
|
7,313
|
|
6,698
|
|
9.2
|
|
3.3
|
|
5.9
|
|
6,972
|
|
6,726
|
|
3.7
|
|
1.9
|
|
1.8
|
|
13,739
|
|
13,019
|
|
5.5
|
|
2.5
|
|
3.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
10,640
|
|
9,726
|
|
9.4
|
|
9.4
|
|
-
|
|
20,591
|
|
19,104
|
|
7.8
|
|
7.8
|
|
-
|
International
|
10,190
|
|
9,113
|
|
11.8
|
|
7.9
|
|
3.9
|
|
20,248
|
|
17,501
|
|
15.7
|
|
9.3
|
|
6.4
|
Worldwide
|
$
20,830
|
|
18,839
|
|
10.6
|
%
|
8.7
|
|
1.9
|
|
$
40,839
|
|
36,605
|
|
11.6
|
%
|
8.6
|
|
3.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2018
|
|
2017
|
|
Total
|
|
Operations
|
|
Currency
|
|
2018
|
|
2017
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
10,640
|
|
9,726
|
|
9.4
|
%
|
9.4
|
|
-
|
|
$
20,591
|
|
19,104
|
|
7.8
|
%
|
7.8
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
4,810
|
|
4,232
|
|
13.7
|
|
6.5
|
|
7.2
|
|
9,607
|
|
8,090
|
|
18.8
|
|
8.2
|
|
10.6
|
Western Hemisphere
excluding U.S.
|
1,540
|
|
1,499
|
|
2.7
|
|
6.7
|
|
(4.0)
|
|
3,107
|
|
2,953
|
|
5.2
|
|
6.9
|
|
(1.7)
|
Asia-Pacific,
Africa
|
3,840
|
|
3,382
|
|
13.5
|
|
10.2
|
|
3.3
|
|
7,534
|
|
6,458
|
|
16.7
|
|
11.9
|
|
4.8
|
International
|
10,190
|
|
9,113
|
|
11.8
|
|
7.9
|
|
3.9
|
|
20,248
|
|
17,501
|
|
15.7
|
|
9.3
|
|
6.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
20,830
|
|
18,839
|
|
10.6
|
%
|
8.7
|
|
1.9
|
|
$
40,839
|
|
36,605
|
|
11.6
|
%
|
8.6
|
|
3.0
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
SECOND
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2018
|
|
|
2017*
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
20,830
|
|
100.0
|
|
$
18,839
|
|
100.0
|
|
10.6
|
Cost of products
sold
|
6,927
|
|
33.3
|
|
5,846
|
|
31.0
|
|
18.5
|
Gross
Profit
|
13,903
|
|
66.7
|
|
12,993
|
|
69.0
|
|
7.0
|
Selling, marketing
and administrative expenses
|
5,743
|
|
27.5
|
|
5,289
|
|
28.1
|
|
8.6
|
Research and
development expense
|
2,639
|
|
12.7
|
|
2,296
|
|
12.2
|
|
14.9
|
Interest (income)
expense, net
|
127
|
|
0.6
|
|
122
|
|
0.6
|
|
|
Other (income)
expense, net
|
364
|
|
1.7
|
|
527
|
|
2.8
|
|
|
Restructuring
|
57
|
|
0.3
|
|
11
|
|
0.1
|
|
|
Earnings before
provision for taxes on income
|
4,973
|
|
23.9
|
|
4,748
|
|
25.2
|
|
4.7
|
Provision for
taxes on income
|
1,019
|
|
4.9
|
|
921
|
|
4.9
|
|
10.6
|
Net
earnings
|
$
3,954
|
|
19.0
|
|
$
3,827
|
|
20.3
|
|
3.3
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.45
|
|
|
|
$
1.40
|
|
|
|
3.6
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,721.3
|
|
|
|
2,741.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
20.5
|
%
|
|
|
19.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
7,014
|
|
33.7
|
|
$
6,285
|
|
33.4
|
|
11.6
|
Net
earnings
|
$
5,718
|
|
27.5
|
|
$
5,017
|
|
26.6
|
|
14.0
|
Net earnings per
share (Diluted)
|
$
2.10
|
|
|
|
$
1.83
|
|
|
|
14.8
|
Effective tax
rate
|
18.5
|
%
|
|
|
20.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
*2017 Statement of
Earnings line items have been restated to reflect impact of ASU
2017-07
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
SIX
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2018
|
|
2017*
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
40,839
|
|
100.0
|
|
$
36,605
|
|
100.0
|
|
11.6
|
Cost of products
sold
|
13,541
|
|
33.2
|
|
11,255
|
|
30.8
|
|
20.3
|
Gross
Profit
|
27,298
|
|
66.8
|
|
25,350
|
|
69.2
|
|
7.7
|
Selling, marketing
and administrative expenses
|
11,006
|
|
27.0
|
|
10,052
|
|
27.5
|
|
9.5
|
Research and
development expense
|
5,043
|
|
12.3
|
|
4,366
|
|
11.9
|
|
15.5
|
Interest (income)
expense, net
|
272
|
|
0.7
|
|
205
|
|
0.6
|
|
|
Other (income)
expense, net
|
424
|
|
1.0
|
|
308
|
|
0.8
|
|
|
Restructuring
|
99
|
|
0.2
|
|
96
|
|
0.2
|
|
|
Earnings before
provision for taxes on income
|
10,454
|
|
25.6
|
|
10,323
|
|
28.2
|
|
1.3
|
Provision for
taxes on income
|
2,133
|
|
5.2
|
|
2,074
|
|
5.7
|
|
2.8
|
Net
earnings
|
$
8,321
|
|
20.4
|
|
$
8,249
|
|
22.5
|
|
0.9
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
3.05
|
|
|
|
$
3.00
|
|
|
|
1.7
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,728.5
|
|
|
|
2,749.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
20.4
|
%
|
|
|
20.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
13,872
|
|
34.0
|
|
$
12,388
|
|
33.8
|
|
12.0
|
Net
earnings
|
$
11,353
|
|
27.8
|
|
$
10,055
|
|
27.5
|
|
12.9
|
Net earnings per
share (Diluted)
|
$
4.16
|
|
|
|
$
3.66
|
|
|
|
13.7
|
Effective tax
rate
|
18.2
|
%
|
|
|
18.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
*2017 Statement of
Earnings line items have been restated to reflect impact of ASU
2017-07
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second
Quarter
|
|
% Incr. /
|
|
|
Six Months
YTD
|
|
% Incr. /
|
|
(Dollars in
Millions Except Per Share Data)
|
|
2018
|
|
2017
|
|
(Decr.)
|
|
|
2018
|
|
2017
|
|
(Decr.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as reported
|
|
$
4,973
|
|
4,748
|
|
4.7
|
%
|
|
$
10,454
|
|
10,323
|
|
1.3
|
%
|
Intangible asset
amortization expense
|
|
1,084
|
|
480
|
|
|
|
|
2,199
|
|
809
|
|
|
|
Litigation expense,
net
|
|
703
|
|
493
|
|
|
|
|
703
|
|
493
|
|
|
|
Restructuring/Other
(1)
|
|
176
|
|
128
|
|
|
|
|
283
|
|
289
|
|
|
|
Actelion acquisition
related cost
|
|
64
|
|
213
|
|
|
|
|
160
|
|
213
|
|
|
|
Diabetes asset
impairment
|
|
4
|
|
182
|
|
|
|
|
4
|
|
182
|
|
|
|
AMO acquisition
related cost
|
|
25
|
|
41
|
|
|
|
|
46
|
|
79
|
|
|
|
Unrealized
loss/(gain) on securities
|
|
(39)
|
|
-
|
|
|
|
|
(12)
|
|
-
|
|
|
|
Other
|
|
24
|
|
-
|
|
|
|
|
35
|
|
-
|
|
|
|
Earnings before
provision for taxes on income - as adjusted
|
|
$
7,014
|
|
6,285
|
|
11.6
|
%
|
|
$
13,872
|
|
12,388
|
|
12.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
reported
|
|
$
3,954
|
|
3,827
|
|
3.3
|
%
|
|
$
8,321
|
|
8,249
|
|
0.9
|
%
|
Intangible asset
amortization expense
|
|
967
|
|
378
|
|
|
|
|
1,963
|
|
622
|
|
|
|
Litigation expense,
net
|
|
609
|
|
352
|
|
|
|
|
609
|
|
352
|
|
|
|
Restructuring/Other
|
|
152
|
|
101
|
|
|
|
|
233
|
|
222
|
|
|
|
Actelion acquisition
related cost
|
|
64
|
|
199
|
|
|
|
|
156
|
|
199
|
|
|
|
Diabetes asset
impairment
|
|
3
|
|
125
|
|
|
|
|
3
|
|
125
|
|
|
|
AMO acquisition
related cost
|
|
22
|
|
35
|
|
|
|
|
39
|
|
286
|
|
|
|
Unrealized
loss/(gain) on securities
|
|
(31)
|
|
-
|
|
|
|
|
(10)
|
|
-
|
|
|
|
Impact of tax
legislation (2)
|
|
(40)
|
|
-
|
|
|
|
|
12
|
|
-
|
|
|
|
Other
|
|
18
|
|
-
|
|
|
|
|
27
|
|
-
|
|
|
|
Net Earnings - as
adjusted
|
|
$
5,718
|
|
5,017
|
|
14.0
|
%
|
|
$
11,353
|
|
10,055
|
|
12.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as reported
|
|
$
1.45
|
|
1.40
|
|
3.6
|
%
|
|
$
3.05
|
|
3.00
|
|
1.7
|
%
|
Intangible asset
amortization expense
|
|
0.36
|
|
0.14
|
|
|
|
|
0.72
|
|
0.23
|
|
|
|
Litigation expense,
net
|
|
0.22
|
|
0.13
|
|
|
|
|
0.22
|
|
0.13
|
|
|
|
Restructuring/Other
|
|
0.06
|
|
0.03
|
|
|
|
|
0.09
|
|
0.08
|
|
|
|
Actelion acquisition
related cost
|
|
0.02
|
|
0.07
|
|
|
|
|
0.05
|
|
0.07
|
|
|
|
Diabetes asset
impairment
|
|
-
|
|
0.05
|
|
|
|
|
-
|
|
0.05
|
|
|
|
AMO acquisition
related cost
|
|
0.01
|
|
0.01
|
|
|
|
|
0.01
|
|
0.10
|
|
|
|
Unrealized
loss/(gain) on securities
|
|
(0.01)
|
|
-
|
|
|
|
|
-
|
|
-
|
|
|
|
Impact of tax
legislation
|
|
(0.02)
|
|
-
|
|
|
|
|
0.01
|
|
-
|
|
|
|
Other
|
|
0.01
|
|
-
|
|
|
|
|
0.01
|
|
-
|
|
|
|
Diluted Net Earnings
per share - as adjusted
|
|
$
2.10
|
|
1.83
|
|
14.8
|
%
|
|
$
4.16
|
|
3.66
|
|
13.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at 2016 foreign
currency exchange rates
|
|
|
|
1.86
|
|
|
|
|
|
|
3.72
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of currency at
2017 foreign currency exchange rates
|
|
(0.06)
|
|
(0.03)
|
|
|
|
|
(0.19)
|
|
(0.06)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at 2017 foreign
currency exchange rates
|
|
$
2.04
|
|
1.83
|
|
11.5
|
%
|
|
$
3.97
|
|
3.66
|
|
8.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)Includes $44M recorded in cost of
products sold and $75M recorded in other (income) expense for the
second quarter 2018. Includes $50M recorded in cost of products
sold
|
|
and $134M recorded in
other (income) expense for six months 2018 YTD. Includes $13M
recorded in cost of products sold and $104M recorded in other
(income) expense for the
|
|
second quarter
2017. Includes $17M recorded in cost of products sold and
$176M recorded in other (income) expense for six months 2017
YTD.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)Includes foreign currency
translation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions and Divestitures
|
SECOND
QUARTER 2018 ACTUAL vs. 2017 ACTUAL
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational
%(1)
|
WW As
Reported:
|
|
(0.4)%
|
|
17.6%
|
|
1.9%
|
|
8.7%
|
U.S.
|
|
(0.7)%
|
|
17.7%
|
|
1.1%
|
|
9.4%
|
International
|
|
0.0%
|
|
17.5%
|
|
2.5%
|
|
7.9%
|
|
|
|
|
|
|
|
|
|
Pulmonary
Hypertension
|
|
|
|
|
|
|
|
|
Actelion
|
|
|
|
(6.3)
|
|
|
|
(3.0)
|
U.S.
|
|
|
|
(7.4)
|
|
|
|
(3.8)
|
International
|
|
|
|
(5.2)
|
|
|
|
(2.0)
|
|
|
|
|
|
|
|
|
|
Cardiovascular /
Metabolism / Other
|
|
|
|
|
|
|
|
|
Actelion
|
|
|
|
(0.3)
|
|
|
|
(0.1)
|
U.S.
|
|
|
|
(0.1)
|
|
|
|
(0.1)
|
International
|
|
|
|
(0.4)
|
|
|
|
(0.2)
|
|
|
|
|
|
|
|
|
|
Spine &
Other
|
|
|
|
|
|
|
|
|
Codman
Neuroscience
|
|
|
|
|
|
1.0
|
|
0.4
|
U.S.
|
|
|
|
|
|
0.6
|
|
0.2
|
International
|
|
|
|
|
|
1.5
|
|
0.6
|
|
|
|
|
|
|
|
|
|
Wound Care /
Other
|
|
1.0
|
|
|
|
|
|
0.2
|
Compeed
|
|
0.0
|
|
|
|
|
|
0.0
|
U.S.
|
|
1.7
|
|
|
|
|
|
0.4
|
International
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.3
|
|
|
|
0.0
|
|
0.1
|
U.S.
|
|
0.0
|
|
|
|
0.0
|
|
0.0
|
International
|
|
0.4
|
|
|
|
0.1
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
0.9%
|
|
11.0%
|
|
2.9%
|
|
6.3%
|
U.S.
|
|
(0.7)%
|
|
10.2%
|
|
1.7%
|
|
5.7%
|
International
|
|
2.1%
|
|
11.9%
|
|
4.1%
|
|
6.8%
|
|
|
|
|
|
|
|
|
|
(1)Operational growth excludes the effect
of translational currency
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales Growth
Excluding Acquisitions and Divestitures
|
SIX MONTHS 2018 ACTUAL
vs. 2017 ACTUAL
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational
%(1)
|
WW As
Reported:
|
|
0.4%
|
|
16.4%
|
|
2.5%
|
|
8.6%
|
U.S.
|
|
0.4%
|
|
13.9%
|
|
1.7%
|
|
7.8%
|
International
|
|
0.5%
|
|
19.9%
|
|
3.3%
|
|
9.3%
|
|
|
|
|
|
|
|
|
|
Pulmonary
Hypertension
|
|
|
|
|
|
|
|
|
Actelion
|
|
|
|
(6.8)
|
|
|
|
(3.1)
|
U.S.
|
|
|
|
(7.4)
|
|
|
|
(3.8)
|
International
|
|
|
|
(5.9)
|
|
|
|
(2.4)
|
|
|
|
|
|
|
|
|
|
Cardiovascular /
Metabolism / Other
|
|
|
|
|
|
|
|
|
Actelion
|
|
|
|
(0.3)
|
|
|
|
(0.2)
|
U.S.
|
|
|
|
(0.2)
|
|
|
|
(0.1)
|
International
|
|
|
|
(0.5)
|
|
|
|
(0.2)
|
|
|
|
|
|
|
|
|
|
Spine &
Other
|
|
|
|
|
|
|
|
|
Codman
Neuroscience
|
|
|
|
|
|
1.0
|
|
0.3
|
U.S.
|
|
|
|
|
|
0.6
|
|
0.2
|
International
|
|
|
|
|
|
1.4
|
|
0.6
|
|
|
|
|
|
|
|
|
|
Wound Care /
Other
|
|
|
|
|
|
|
|
|
Compeed
|
|
0.9
|
|
|
|
|
|
0.2
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
1.5
|
|
|
|
|
|
0.4
|
|
|
|
|
|
|
|
|
|
Vision
|
|
|
|
|
|
|
|
|
Vision Surgical & Eye Health Business
|
|
|
|
|
|
(1.5)
|
|
(0.5)
|
U.S.
|
|
|
|
|
|
(1.4)
|
|
(0.5)
|
International
|
|
|
|
|
|
(1.6)
|
|
(0.6)
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.1
|
|
|
|
0.0
|
|
0.0
|
U.S.
|
|
0.0
|
|
|
|
(0.2)
|
|
0.0
|
International
|
|
0.3
|
|
|
|
0.1
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
1.4%
|
|
9.3%
|
|
2.0%
|
|
5.3%
|
U.S.
|
|
0.4%
|
|
6.3%
|
|
0.7%
|
|
3.6%
|
International
|
|
2.3%
|
|
13.5%
|
|
3.2%
|
|
7.2%
|
|
|
|
|
|
|
|
|
|
(1)Operational growth excludes the effect
of translational currency
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER SEGMENT
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
89
|
|
$
113
|
-21.2%
|
-21.2%
|
-
|
|
|
$
186
|
|
$
226
|
-17.7%
|
-17.7%
|
-
|
Intl
|
|
367
|
|
381
|
-3.7%
|
-2.7%
|
-1.0%
|
|
|
727
|
|
723
|
0.6%
|
-0.8%
|
1.4%
|
WW
|
|
456
|
|
494
|
-7.7%
|
-6.9%
|
-0.8%
|
|
|
913
|
|
949
|
-3.8%
|
-4.8%
|
1.0%
|
BEAUTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
637
|
|
649
|
-1.8%
|
-1.8%
|
-
|
|
|
1,248
|
|
1,216
|
2.6%
|
2.6%
|
-
|
Intl
|
|
472
|
|
427
|
10.5%
|
7.3%
|
3.2%
|
|
|
945
|
|
841
|
12.4%
|
6.8%
|
5.6%
|
WW
|
|
1,109
|
|
1,076
|
3.1%
|
1.8%
|
1.3%
|
|
|
2,193
|
|
2,057
|
6.6%
|
4.3%
|
2.3%
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
157
|
|
150
|
4.7%
|
4.7%
|
-
|
|
|
314
|
|
306
|
2.6%
|
2.6%
|
-
|
Intl
|
|
236
|
|
244
|
-3.3%
|
-5.5%
|
2.2%
|
|
|
458
|
|
450
|
1.8%
|
-2.7%
|
4.5%
|
WW
|
|
393
|
|
394
|
-0.3%
|
-1.7%
|
1.4%
|
|
|
772
|
|
756
|
2.1%
|
-0.6%
|
2.7%
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
454
|
|
432
|
5.1%
|
5.1%
|
-
|
|
|
919
|
|
909
|
1.1%
|
1.1%
|
-
|
Intl
|
|
612
|
|
574
|
6.6%
|
2.5%
|
4.1%
|
|
|
1,219
|
|
1,110
|
9.8%
|
3.2%
|
6.6%
|
WW
|
|
1,066
|
|
1,006
|
6.0%
|
3.7%
|
2.3%
|
|
|
2,138
|
|
2,019
|
5.9%
|
2.2%
|
3.7%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
4
|
|
3
|
33.3%
|
33.3%
|
-
|
|
|
7
|
|
6
|
16.7%
|
16.7%
|
-
|
Intl
|
|
276
|
|
273
|
1.1%
|
1.9%
|
-0.8%
|
|
|
516
|
|
512
|
0.8%
|
-1.1%
|
1.9%
|
WW
|
|
280
|
|
276
|
1.4%
|
2.2%
|
-0.8%
|
|
|
523
|
|
518
|
1.0%
|
-0.9%
|
1.9%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
135
|
|
140
|
-3.6%
|
-3.6%
|
-
|
|
|
238
|
|
238
|
0.0%
|
0.0%
|
-
|
Intl
|
|
65
|
|
92
|
-29.3%
|
-31.3%
|
2.0%
|
|
|
125
|
|
169
|
-26.0%
|
-29.2%
|
3.2%
|
WW
|
|
200
|
|
232
|
-13.8%
|
-14.6%
|
0.8%
|
|
|
363
|
|
407
|
-10.8%
|
-12.1%
|
1.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
CONSUMER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,476
|
|
1,487
|
-0.7%
|
-0.7%
|
-
|
|
|
2,912
|
|
2,901
|
0.4%
|
0.4%
|
-
|
Intl
|
|
2,028
|
|
1,991
|
1.9%
|
0.0%
|
1.9%
|
|
|
3,990
|
|
3,805
|
4.9%
|
0.5%
|
4.4%
|
WW
|
|
$
3,504
|
|
$
3,478
|
0.7%
|
-0.4%
|
1.1%
|
|
|
$
6,902
|
|
$
6,706
|
2.9%
|
0.4%
|
2.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
PHARMACEUTICAL
SEGMENT (2)(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
2,317
|
|
$
2,101
|
10.3%
|
10.3%
|
-
|
|
|
$
4,317
|
|
$
4,224
|
2.2%
|
2.2%
|
-
|
Intl
|
|
1,021
|
|
858
|
19.0%
|
14.6%
|
4.4%
|
|
|
2,063
|
|
1,665
|
23.9%
|
17.0%
|
6.9%
|
WW
|
|
3,338
|
|
2,959
|
12.8%
|
11.5%
|
1.3%
|
|
|
6,380
|
|
5,889
|
8.3%
|
6.3%
|
2.0%
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
918
|
|
1,064
|
-13.7%
|
-13.7%
|
-
|
|
|
1,834
|
|
2,246
|
-18.3%
|
-18.3%
|
-
|
US Exports
(3)
|
|
104
|
|
127
|
-18.1%
|
-18.1%
|
-
|
|
|
246
|
|
292
|
-15.8%
|
-15.8%
|
-
|
Intl
|
|
298
|
|
339
|
-12.1%
|
-14.0%
|
1.9%
|
|
|
629
|
|
664
|
-5.3%
|
-9.0%
|
3.7%
|
WW
|
|
1,320
|
|
1,530
|
-13.7%
|
-14.1%
|
0.4%
|
|
|
2,709
|
|
3,202
|
-15.4%
|
-16.2%
|
0.8%
|
SIMPONI / SIMPONI
ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
274
|
|
230
|
19.1%
|
19.1%
|
-
|
|
|
498
|
|
459
|
8.5%
|
8.5%
|
-
|
Intl
|
|
274
|
|
209
|
31.1%
|
26.9%
|
4.2%
|
|
|
568
|
|
408
|
39.2%
|
32.0%
|
7.2%
|
WW
|
|
548
|
|
439
|
24.8%
|
22.8%
|
2.0%
|
|
|
1,066
|
|
867
|
23.0%
|
19.6%
|
3.4%
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
919
|
|
680
|
35.1%
|
35.1%
|
-
|
|
|
1,571
|
|
1,227
|
28.0%
|
28.0%
|
-
|
Intl
|
|
422
|
|
303
|
39.3%
|
32.0%
|
7.3%
|
|
|
831
|
|
579
|
43.5%
|
32.9%
|
10.6%
|
WW
|
|
1,341
|
|
983
|
36.4%
|
34.2%
|
2.2%
|
|
|
2,402
|
|
1,806
|
33.0%
|
29.6%
|
3.4%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
102
|
|
-
|
*
|
*
|
-
|
|
|
168
|
|
-
|
*
|
*
|
-
|
Intl
|
|
27
|
|
7
|
*
|
*
|
*
|
|
|
35
|
|
14
|
*
|
*
|
*
|
WW
|
|
129
|
|
7
|
*
|
*
|
*
|
|
|
203
|
|
14
|
*
|
*
|
*
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
328
|
|
341
|
-3.8%
|
-3.8%
|
-
|
|
|
661
|
|
667
|
-0.9%
|
-0.9%
|
-
|
Intl
|
|
521
|
|
451
|
15.5%
|
11.0%
|
4.5%
|
|
|
1,018
|
|
874
|
16.5%
|
8.5%
|
8.0%
|
WW
|
|
849
|
|
792
|
7.2%
|
4.6%
|
2.6%
|
|
|
1,679
|
|
1,541
|
9.0%
|
4.5%
|
4.5%
|
EDURANT /
rilpivirine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
15
|
|
17
|
-11.8%
|
-11.8%
|
-
|
|
|
29
|
|
29
|
0.0%
|
0.0%
|
-
|
Intl
|
|
196
|
|
162
|
21.0%
|
13.1%
|
7.9%
|
|
|
392
|
|
299
|
31.1%
|
18.6%
|
12.5%
|
WW
|
|
211
|
|
179
|
17.9%
|
10.7%
|
7.2%
|
|
|
421
|
|
328
|
28.4%
|
17.0%
|
11.4%
|
PREZISTA / PREZCOBIX /
REZOLSTA / SYMTUZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
277
|
|
278
|
-0.4%
|
-0.4%
|
-
|
|
|
550
|
|
537
|
2.4%
|
2.4%
|
-
|
Intl
|
|
215
|
|
176
|
22.2%
|
18.8%
|
3.4%
|
|
|
420
|
|
347
|
21.0%
|
14.1%
|
6.9%
|
WW
|
|
492
|
|
454
|
8.4%
|
7.1%
|
1.3%
|
|
|
970
|
|
884
|
9.7%
|
7.0%
|
2.7%
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
36
|
|
46
|
-21.7%
|
-21.7%
|
-
|
|
|
82
|
|
101
|
-18.8%
|
-18.8%
|
-
|
Intl
|
|
110
|
|
113
|
-2.7%
|
-4.1%
|
1.4%
|
|
|
206
|
|
228
|
-9.6%
|
-13.3%
|
3.7%
|
WW
|
|
146
|
|
159
|
-8.2%
|
-9.2%
|
1.0%
|
|
|
288
|
|
329
|
-12.5%
|
-15.1%
|
2.6%
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
639
|
|
620
|
3.1%
|
3.1%
|
-
|
|
|
1,263
|
|
1,284
|
-1.6%
|
-1.6%
|
-
|
Intl
|
|
889
|
|
847
|
5.0%
|
1.4%
|
3.6%
|
|
|
1,824
|
|
1,680
|
8.6%
|
2.4%
|
6.2%
|
WW
|
|
1,528
|
|
1,467
|
4.2%
|
2.1%
|
2.1%
|
|
|
3,087
|
|
2,964
|
4.1%
|
0.6%
|
3.5%
|
CONCERTA /
methlyphenidate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
68
|
|
76
|
-10.5%
|
-10.5%
|
-
|
|
|
134
|
|
184
|
-27.2%
|
-27.2%
|
-
|
Intl
|
|
115
|
|
105
|
9.5%
|
6.9%
|
2.6%
|
|
|
222
|
|
206
|
7.8%
|
3.1%
|
4.7%
|
WW
|
|
183
|
|
181
|
1.1%
|
-0.4%
|
1.5%
|
|
|
356
|
|
390
|
-8.7%
|
-11.2%
|
2.5%
|
INVEGA SUSTENNA /
XEPLION / TRINZA / TREVICTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
438
|
|
387
|
13.2%
|
13.2%
|
-
|
|
|
838
|
|
759
|
10.4%
|
10.4%
|
-
|
Intl
|
|
282
|
|
242
|
16.5%
|
10.5%
|
6.0%
|
|
|
578
|
|
474
|
21.9%
|
12.8%
|
9.1%
|
WW
|
|
720
|
|
629
|
14.5%
|
12.2%
|
2.3%
|
|
|
1,416
|
|
1,233
|
14.8%
|
11.3%
|
3.5%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
80
|
|
91
|
-12.1%
|
-12.1%
|
-
|
|
|
162
|
|
186
|
-12.9%
|
-12.9%
|
-
|
Intl
|
|
108
|
|
116
|
-6.9%
|
-10.3%
|
3.4%
|
|
|
222
|
|
228
|
-2.6%
|
-8.7%
|
6.1%
|
WW
|
|
188
|
|
207
|
-9.2%
|
-11.1%
|
1.9%
|
|
|
384
|
|
414
|
-7.2%
|
-10.6%
|
3.4%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
53
|
|
66
|
-19.7%
|
-19.7%
|
-
|
|
|
129
|
|
155
|
-16.8%
|
-16.8%
|
-
|
Intl
|
|
384
|
|
384
|
0.0%
|
-2.4%
|
2.4%
|
|
|
802
|
|
772
|
3.9%
|
-1.0%
|
4.9%
|
WW
|
|
437
|
|
450
|
-2.9%
|
-5.0%
|
2.1%
|
|
|
931
|
|
927
|
0.4%
|
-3.6%
|
4.0%
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,085
|
|
697
|
55.7%
|
55.7%
|
-
|
|
|
2,018
|
|
1,361
|
48.3%
|
48.3%
|
-
|
Intl
|
|
1,371
|
|
1,030
|
33.1%
|
27.2%
|
5.9%
|
|
|
2,749
|
|
1,960
|
40.3%
|
30.7%
|
9.6%
|
WW
|
|
2,456
|
|
1,727
|
42.2%
|
38.7%
|
3.5%
|
|
|
4,767
|
|
3,321
|
43.5%
|
37.8%
|
5.7%
|
DARZALEX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
298
|
|
212
|
40.6%
|
40.6%
|
-
|
|
|
562
|
|
413
|
36.1%
|
36.1%
|
-
|
Intl
|
|
213
|
|
87
|
*
|
*
|
*
|
|
|
381
|
|
141
|
*
|
*
|
*
|
WW
|
|
511
|
|
299
|
70.9%
|
67.7%
|
3.2%
|
|
|
943
|
|
554
|
70.2%
|
65.8%
|
4.4%
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
250
|
|
202
|
23.8%
|
23.8%
|
-
|
|
|
477
|
|
392
|
21.7%
|
21.7%
|
-
|
Intl
|
|
370
|
|
248
|
49.2%
|
42.7%
|
6.5%
|
|
|
730
|
|
467
|
56.3%
|
45.7%
|
10.6%
|
WW
|
|
620
|
|
450
|
37.8%
|
34.2%
|
3.6%
|
|
|
1,207
|
|
859
|
40.5%
|
34.7%
|
5.8%
|
VELCADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
280
|
|
290
|
-3.4%
|
-8.0%
|
4.6%
|
|
|
593
|
|
570
|
4.0%
|
-3.4%
|
7.4%
|
WW
|
|
280
|
|
290
|
-3.4%
|
-8.0%
|
4.6%
|
|
|
593
|
|
570
|
4.0%
|
-3.4%
|
7.4%
|
ZYTIGA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
486
|
|
241
|
*
|
*
|
-
|
|
|
893
|
|
474
|
88.4%
|
88.4%
|
-
|
Intl
|
|
423
|
|
317
|
33.4%
|
27.3%
|
6.1%
|
|
|
861
|
|
607
|
41.8%
|
31.8%
|
10.0%
|
WW
|
|
909
|
|
558
|
62.9%
|
59.5%
|
3.4%
|
|
|
1,754
|
|
1,081
|
62.3%
|
56.7%
|
5.6%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
51
|
|
42
|
21.4%
|
21.4%
|
-
|
|
|
86
|
|
82
|
4.9%
|
4.9%
|
-
|
Intl
|
|
85
|
|
88
|
-3.4%
|
-6.8%
|
3.4%
|
|
|
184
|
|
175
|
5.1%
|
-1.5%
|
6.6%
|
WW
|
|
136
|
|
130
|
4.6%
|
2.3%
|
2.3%
|
|
|
270
|
|
257
|
5.1%
|
0.6%
|
4.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
|
|
PULMONARY
HYPERTENSION(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
429
|
|
37
|
*
|
*
|
-
|
|
|
790
|
|
37
|
*
|
*
|
-
|
|
|
Intl
|
|
236
|
|
48
|
*
|
*
|
*
|
|
|
460
|
|
48
|
*
|
*
|
*
|
|
|
WW
|
|
665
|
|
85
|
*
|
*
|
*
|
|
|
1,250
|
|
85
|
*
|
*
|
*
|
|
|
OPSUMIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
180
|
|
24
|
*
|
*
|
-
|
|
|
329
|
|
24
|
*
|
*
|
-
|
|
|
Intl
|
|
131
|
|
21
|
*
|
*
|
*
|
|
|
253
|
|
21
|
*
|
*
|
*
|
|
|
WW
|
|
311
|
|
45
|
*
|
*
|
*
|
|
|
582
|
|
45
|
*
|
*
|
*
|
|
|
TRACLEER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
71
|
|
2
|
*
|
*
|
-
|
|
|
139
|
|
2
|
*
|
*
|
-
|
|
|
Intl
|
|
72
|
|
24
|
*
|
*
|
*
|
|
|
144
|
|
24
|
*
|
*
|
*
|
|
|
WW
|
|
143
|
|
26
|
*
|
*
|
*
|
|
|
283
|
|
26
|
*
|
*
|
*
|
|
|
UPTRAVI
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
155
|
|
8
|
*
|
*
|
-
|
|
|
279
|
|
8
|
*
|
*
|
-
|
|
|
Intl
|
|
16
|
|
1
|
*
|
*
|
*
|
|
|
32
|
|
1
|
*
|
*
|
*
|
|
|
WW
|
|
171
|
|
9
|
*
|
*
|
*
|
|
|
311
|
|
9
|
*
|
*
|
*
|
|
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
23
|
|
3
|
*
|
*
|
-
|
|
|
43
|
|
3
|
*
|
*
|
-
|
|
|
Intl
|
|
17
|
|
2
|
*
|
*
|
*
|
|
|
31
|
|
2
|
*
|
*
|
*
|
|
|
WW
|
|
40
|
|
5
|
*
|
*
|
*
|
|
|
74
|
|
5
|
*
|
*
|
*
|
|
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,101
|
|
1,214
|
-9.3%
|
-9.3%
|
-
|
|
|
2,204
|
|
2,309
|
-4.5%
|
-4.5%
|
-
|
|
|
Intl
|
|
417
|
|
391
|
6.6%
|
1.9%
|
4.7%
|
|
|
831
|
|
771
|
7.8%
|
1.7%
|
6.1%
|
|
|
WW
|
|
1,518
|
|
1,605
|
-5.4%
|
-6.6%
|
1.2%
|
|
|
3,035
|
|
3,080
|
-1.5%
|
-3.0%
|
1.5%
|
|
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
679
|
|
642
|
5.8%
|
5.8%
|
-
|
|
|
1,257
|
|
1,155
|
8.8%
|
8.8%
|
-
|
|
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
WW
|
|
679
|
|
642
|
5.8%
|
5.8%
|
-
|
|
|
1,257
|
|
1,155
|
8.8%
|
8.8%
|
-
|
|
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
169
|
|
256
|
-34.0%
|
-34.0%
|
-
|
|
|
373
|
|
503
|
-25.8%
|
-25.8%
|
-
|
|
|
Intl
|
|
46
|
|
39
|
17.9%
|
13.0%
|
4.9%
|
|
|
90
|
|
76
|
18.4%
|
11.7%
|
6.7%
|
|
|
WW
|
|
215
|
|
295
|
-27.1%
|
-27.7%
|
0.6%
|
|
|
463
|
|
579
|
-20.0%
|
-20.9%
|
0.9%
|
|
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
156
|
|
174
|
-10.3%
|
-10.3%
|
-
|
|
|
345
|
|
343
|
0.6%
|
0.6%
|
-
|
|
|
Intl
|
|
80
|
|
81
|
-1.2%
|
-5.9%
|
4.7%
|
|
|
167
|
|
159
|
5.0%
|
-1.7%
|
6.7%
|
|
|
WW
|
|
236
|
|
255
|
-7.5%
|
-9.0%
|
1.5%
|
|
|
512
|
|
502
|
2.0%
|
-0.1%
|
2.1%
|
|
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
97
|
|
142
|
-31.7%
|
-31.7%
|
-
|
|
|
229
|
|
308
|
-25.6%
|
-25.6%
|
-
|
|
|
Intl
|
|
291
|
|
271
|
7.4%
|
2.7%
|
4.7%
|
|
|
574
|
|
536
|
7.1%
|
1.3%
|
5.8%
|
|
|
WW
|
|
388
|
|
413
|
-6.1%
|
-9.2%
|
3.1%
|
|
|
803
|
|
844
|
-4.9%
|
-8.6%
|
3.7%
|
|
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
5,899
|
|
5,010
|
17.7%
|
17.7%
|
-
|
|
|
11,253
|
|
9,882
|
13.9%
|
13.9%
|
-
|
|
|
Intl
|
|
4,455
|
|
3,625
|
22.9%
|
17.5%
|
5.4%
|
|
|
8,945
|
|
6,998
|
27.8%
|
19.9%
|
7.9%
|
|
|
WW
|
|
$
10,354
|
|
$
8,635
|
19.9%
|
17.6%
|
2.3%
|
|
|
$
20,198
|
|
$
16,880
|
19.7%
|
16.4%
|
3.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2018
|
|
2017
|
Reported
|
Operational
(1)
|
Currency
|
|
|
MEDICAL DEVICES
SEGMENT (2)(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DIABETES
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
129
|
|
$
160
|
-19.4%
|
-19.4%
|
-
|
|
|
$
246
|
|
$
314
|
-21.7%
|
-21.7%
|
-
|
|
|
Intl
|
|
226
|
|
261
|
-13.4%
|
-16.3%
|
2.9%
|
|
|
448
|
|
506
|
-11.5%
|
-16.6%
|
5.1%
|
|
|
WW
|
|
355
|
|
421
|
-15.7%
|
-17.5%
|
1.8%
|
|
|
694
|
|
820
|
-15.4%
|
-18.5%
|
3.1%
|
|
|
DIAGNOSTICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
1
|
*
|
*
|
*
|
|
|
WW
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
1
|
*
|
*
|
*
|
|
|
INTERVENTIONAL
SOLUTIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
323
|
|
285
|
13.3%
|
13.3%
|
0.0%
|
|
|
627
|
|
564
|
11.2%
|
11.2%
|
-
|
|
|
Intl
|
|
344
|
|
288
|
19.4%
|
14.1%
|
5.3%
|
|
|
680
|
|
558
|
21.9%
|
14.2%
|
7.7%
|
|
|
WW
|
|
667
|
|
573
|
16.4%
|
13.7%
|
2.7%
|
|
|
1,307
|
|
1,122
|
16.5%
|
12.7%
|
3.8%
|
|
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,332
|
|
1,367
|
-2.6%
|
-2.6%
|
-
|
|
|
2,639
|
|
2,726
|
-3.2%
|
-3.2%
|
-
|
|
|
Intl
|
|
930
|
|
926
|
0.4%
|
-3.6%
|
4.0%
|
|
|
1,873
|
|
1,842
|
1.7%
|
-4.6%
|
6.3%
|
|
|
WW
|
|
2,262
|
|
2,293
|
-1.4%
|
-3.0%
|
1.6%
|
|
|
4,512
|
|
4,568
|
-1.2%
|
-3.8%
|
2.6%
|
|
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
211
|
|
208
|
1.4%
|
1.4%
|
-
|
|
|
420
|
|
417
|
0.7%
|
0.7%
|
-
|
|
|
Intl
|
|
149
|
|
142
|
4.9%
|
0.8%
|
4.1%
|
|
|
303
|
|
285
|
6.3%
|
-0.2%
|
6.5%
|
|
|
WW
|
|
360
|
|
350
|
2.9%
|
1.2%
|
1.7%
|
|
|
723
|
|
702
|
3.0%
|
0.3%
|
2.7%
|
|
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
229
|
|
236
|
-3.0%
|
-3.0%
|
-
|
|
|
457
|
|
482
|
-5.2%
|
-5.2%
|
-
|
|
|
Intl
|
|
153
|
|
149
|
2.7%
|
-0.8%
|
3.5%
|
|
|
312
|
|
301
|
3.7%
|
-2.5%
|
6.2%
|
|
|
WW
|
|
382
|
|
385
|
-0.8%
|
-2.2%
|
1.4%
|
|
|
769
|
|
783
|
-1.8%
|
-4.2%
|
2.4%
|
|
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
394
|
|
390
|
1.0%
|
1.0%
|
-
|
|
|
801
|
|
781
|
2.6%
|
2.6%
|
-
|
|
|
Intl
|
|
281
|
|
253
|
11.1%
|
6.7%
|
4.4%
|
|
|
570
|
|
504
|
13.1%
|
6.2%
|
6.9%
|
|
|
WW
|
|
675
|
|
643
|
5.0%
|
3.3%
|
1.7%
|
|
|
1,371
|
|
1,285
|
6.7%
|
4.0%
|
2.7%
|
|
|
SPINE &
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
498
|
|
533
|
-6.6%
|
-6.6%
|
-
|
|
|
961
|
|
1,046
|
-8.1%
|
-8.1%
|
-
|
|
|
Intl
|
|
347
|
|
382
|
-9.2%
|
-13.2%
|
4.0%
|
|
|
688
|
|
752
|
-8.5%
|
-14.5%
|
6.0%
|
|
|
WW
|
|
845
|
|
915
|
-7.7%
|
-9.4%
|
1.7%
|
|
|
1,649
|
|
1,798
|
-8.3%
|
-10.8%
|
2.5%
|
|
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,022
|
|
1,012
|
1.0%
|
1.0%
|
-
|
|
|
2,015
|
|
2,007
|
0.4%
|
0.4%
|
-
|
|
|
Intl
|
|
1,493
|
|
1,372
|
8.8%
|
5.4%
|
3.4%
|
|
|
2,923
|
|
2,648
|
10.4%
|
4.7%
|
5.7%
|
|
|
WW
|
|
2,515
|
|
2,384
|
5.5%
|
3.5%
|
2.0%
|
|
|
4,938
|
|
4,655
|
6.1%
|
2.9%
|
3.2%
|
|
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
402
|
|
400
|
0.5%
|
0.5%
|
-
|
|
|
795
|
|
792
|
0.4%
|
0.4%
|
-
|
|
|
Intl
|
|
603
|
|
533
|
13.1%
|
9.1%
|
4.0%
|
|
|
1,176
|
|
1,018
|
15.5%
|
9.3%
|
6.2%
|
|
|
WW
|
|
1,005
|
|
933
|
7.7%
|
5.4%
|
2.3%
|
|
|
1,971
|
|
1,810
|
8.9%
|
5.4%
|
3.5%
|
|
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
436
|
|
423
|
3.1%
|
3.1%
|
-
|
|
|
859
|
|
846
|
1.5%
|
1.5%
|
-
|
|
|
Intl
|
|
733
|
|
691
|
6.1%
|
2.9%
|
3.2%
|
|
|
1,437
|
|
1,342
|
7.1%
|
1.5%
|
5.6%
|
|
|
WW
|
|
1,169
|
|
1,114
|
4.9%
|
2.9%
|
2.0%
|
|
|
2,296
|
|
2,188
|
4.9%
|
1.5%
|
3.4%
|
|
|
SPECIALTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
184
|
|
189
|
-2.6%
|
-2.6%
|
-
|
|
|
361
|
|
369
|
-2.2%
|
-2.2%
|
-
|
|
|
Intl
|
|
157
|
|
148
|
6.1%
|
4.2%
|
1.9%
|
|
|
310
|
|
288
|
7.6%
|
3.4%
|
4.2%
|
|
|
WW
|
|
341
|
|
337
|
1.2%
|
0.4%
|
0.8%
|
|
|
671
|
|
657
|
2.1%
|
0.3%
|
1.8%
|
|
|
VISION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
459
|
|
405
|
13.3%
|
13.3%
|
-
|
|
|
899
|
|
710
|
26.6%
|
26.6%
|
-
|
|
|
Intl
|
|
714
|
|
650
|
9.8%
|
7.2%
|
2.6%
|
|
|
1,389
|
|
1,143
|
21.5%
|
16.3%
|
5.2%
|
|
|
WW
|
|
1,173
|
|
1,055
|
11.2%
|
9.6%
|
1.6%
|
|
|
2,288
|
|
1,853
|
23.5%
|
20.3%
|
3.2%
|
|
|
CONTACT LENSES /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
320
|
|
274
|
16.8%
|
16.8%
|
-
|
|
|
629
|
|
530
|
18.7%
|
18.7%
|
-
|
|
|
Intl
|
|
524
|
|
479
|
9.4%
|
6.8%
|
2.6%
|
|
|
1,022
|
|
906
|
12.8%
|
8.0%
|
4.8%
|
|
|
WW
|
|
844
|
|
753
|
12.1%
|
10.4%
|
1.7%
|
|
|
1,651
|
|
1,436
|
15.0%
|
12.0%
|
3.0%
|
|
|
SURGICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
139
|
|
131
|
6.1%
|
6.1%
|
-
|
|
|
270
|
|
180
|
50.0%
|
50.0%
|
-
|
|
|
Intl
|
|
190
|
|
171
|
11.1%
|
8.6%
|
2.5%
|
|
|
367
|
|
237
|
54.9%
|
48.3%
|
6.6%
|
|
|
WW
|
|
329
|
|
302
|
8.9%
|
7.5%
|
1.4%
|
|
|
637
|
|
417
|
52.8%
|
49.1%
|
3.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,265
|
|
3,229
|
1.1%
|
1.1%
|
-
|
|
|
6,426
|
|
6,321
|
1.7%
|
1.7%
|
-
|
|
|
Intl
|
|
3,707
|
|
3,497
|
6.0%
|
2.5%
|
3.5%
|
|
|
7,313
|
|
6,698
|
9.2%
|
3.3%
|
5.9%
|
|
|
WW
|
|
$
6,972
|
|
6,726
|
3.7%
|
1.9%
|
1.8%
|
|
|
$
13,739
|
|
$
13,019
|
5.5%
|
2.5%
|
3.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100% or not meaningful
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Operational
growth excludes the effect of translational currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3) Reported as U.S.
sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4) Products acquired
from Actelion acquisition on June 16, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5) Prior year
amounts have been reclassified to conform to current year product
disclosure
|
|
|
|
|
|
|
|
|
|
|
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2018-second-quarter-results-300682014.html
SOURCE Johnson & Johnson